Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emili Montserrat

Showing results (11-20 of 184) with videos related to

Pageof 19
Sort By:
Oncology (Williston Park, N.Y.)|January 22, 2013
CLL therapy: the increasing importance of predictive markersEmili Montserrat
The Lancet. Haematology|December 22, 2015
Primary CNS lymphoma: in search of the evidenceEmili Montserrat
Blood|July 18, 2009
Unfolding a CLL mysteryEmili Montserrat
Blood|August 8, 2008
Further progress in CLL therapyEmili Montserrat
Blood|September 4, 2020
When CLL meets COVID-19Emili Montserrat
Reviews in Clinical and Experimental Hematology|June 26, 2003
Refining prognostic factors in chronic lymphocytic leukemiaFrancesc Bosch, Emili Montserrat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2015
Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantationEmili Montserrat, Peter Dreger
The Lancet. Haematology|February 3, 2019
Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemiaStefano Molica, Emili Montserrat
The Lancet. Haematology|January 17, 2017
CLL: when the target of treatment is disease-related symptomsStefano Molica, Emili Montserrat
Cancer Journal (Sudbury, Mass.)|August 16, 2021
Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We GoRobin Foà, Emili Montserrat
Pageof 19

Showing results (11-20 of 184) with videos related to

Sort By:
Pageof 19
Oncology (Williston Park, N.Y.)|January 22, 2013
CLL therapy: the increasing importance of predictive markersEmili Montserrat
The Lancet. Haematology|December 22, 2015
Primary CNS lymphoma: in search of the evidenceEmili Montserrat
Blood|July 18, 2009
Unfolding a CLL mysteryEmili Montserrat
Blood|August 8, 2008
Further progress in CLL therapyEmili Montserrat
Blood|September 4, 2020
When CLL meets COVID-19Emili Montserrat
Reviews in Clinical and Experimental Hematology|June 26, 2003
Refining prognostic factors in chronic lymphocytic leukemiaFrancesc Bosch, Emili Montserrat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2015
Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantationEmili Montserrat, Peter Dreger
The Lancet. Haematology|February 3, 2019
Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemiaStefano Molica, Emili Montserrat
The Lancet. Haematology|January 17, 2017
CLL: when the target of treatment is disease-related symptomsStefano Molica, Emili Montserrat
Cancer Journal (Sudbury, Mass.)|August 16, 2021
Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We GoRobin Foà, Emili Montserrat
Pageof 19